Barasertib (dihydrochloride)

Barasertib (AZD1152 dihydrochloride), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152 dihydrochloride) induces growth arrest and apoptosis in cancer cells[1].

Product Specifications

CAS Number

[722543-50-2]

Product Name Alternative

AZD1152 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; Aurora Kinase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/barasertib-dihydrochloride.html

Solubility

10 mM in DMSO

Smiles

O=C(CC1=NNC(NC2=C3C=CC(OCCCN(CCOP(O)(O)=O)CC)=CC3=NC=N2)=C1)NC4=CC(F)=CC=C4.Cl.Cl

Molecular Formula

C26H33Cl2FN7O6P

Molecular Weight

660.46

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Yang J, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep|[2]Oke A, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009 May 15;69 (10) :4150-8.|[3]Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007 Jun 15;13 (12) :3682-8.